ClinicalTrials.gg
CompletedNCT03211403Updated Mar 21, 2018

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

A Phase 1 interventional study of SHR4640 in Gout and Hyperuricemia, sponsored by Atridia Pty Ltd.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
9th of 11
24 · median 50
Started
2017
with 1 other
Phase 1
7 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 1, and was the 5th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

This is a single-Center, randomized, double-Blind, placebo-controlled, multiple ascending-dose Phase I trail.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged between 18 and 65 years, inclusive.
  2. Body weight ≥ 50 kg and between 18.0 and 35.0 kg/m2, inclusive.
  3. Screening sUA level ≥0.36 mmol/L.
  4. Considered generally healthy upon completion of medical history, full physical examination, vital signs, laboratory parameters (including thyroid function and serological tests, hematology, urinalysis, and biochemistry), 12-lead , and abdominal ultrasound, as judged by the Investigator.
  5. Agrees to use a highly effective method of , i.e. condom and suitable contraception for his female partner e.g. oral contraceptive or intrauterine contraceptive device during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence throughout the study period and for 30 days following final dose of study drug, and must agree to refrain from sperm donation from Day -2 until at least 30 days following final dose of study drug.
  6. Negative drug screen (including alcohol) at screening and on admission to clinical site.
  7. Able to understand the study procedures and the risks involved and must be willing to provide a written before any study-related activity.

Exclusion criteria

Exclusion Criteria:

  1. History of to SHR4640 or its analogues.
  2. History of gout.
  3. Screening , aspartate aminotransferase, total , or gamma glutamyl transferase > 1.5 × .
  4. Positive result for (HIV).
  5. Positive result for surface antigen or virus antibody.
  6. History or presence of kidney stones.
  7. Acute or chronic illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk to the subject when administering the trial product.
  8. Undergone major surgery within 3 months of Day 1 or has surgery planned during study participation.
  9. Donated any blood or plasma in the past month or more than 400 mL within 3 months of Day 1.
  10. Has unsuitable venous for blood sampling.
  11. Use of tobacco products within 30 days of Day 1.
  12. Heavy caffeine drinker (more than 5 cups or glasses of caffeinated beverages per day).
  13. History of drug and/or alcohol abuse in the last year.
  14. Consumes more than 14 units of alcohol per week (1 unit = 250 mL beer, 25 mL of 40% spirits and 125 mL glass of wine).
  15. Consumes grapefruit and/or poppy seed within 5 days of Day 1.
  16. Unable to refrain from strenuous exercises, tobacco products, alcohol, grapefruit, and/or poppy seed from Day -2 to Day 10.
  17. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
  1. Prescription medication within 2 weeks of Day 1. 2) Over-the-counter medication within 1 week of Day 1. 3) Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 1 month of Day 1.
  1. Received the last dose of a study drug (or treatment with a medical device) within 30 days or 5 T1/2 (whichever is longer) of the study drug of Day 1 or are currently participating in another study of a study drug (or medical device).
  1. Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or to complete the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    SHR4640 2.5mg

    6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo

    Drug: SHR4640

  • Experimental
    SHR4640 10mg

    6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo

    Drug: SHR4640

  • Experimental
    SHR4640 20mg

    6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo

    Drug: SHR4640

Interventions

  • SHR4640 or placebo once daily for a week

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events in terms of changes in Hematology

    Hemoglobin Hematocrit Erythrocytes count Mean cell volume, Mean cell hemoglobin concentration, Leukocytes count, Neutrophils count, Lymphocytes count, Monocytes count, Eosinophils count, Basophils count, Platelets count

    Time frame: Up to Day 14

  2. Incidence of Adverse events in terms of changes in Urinalysis

    Urobilinogen Dipstick urinalysis, including: pH, Specific gravity, Protein, Blood, Leukocytes, Glucose, Ketones, Bilirubin, Nitrites

    Time frame: Up to Day 14

  3. Incidence of Adverse events in terms of changes in Biochemistry (fasting)

    Including Serum creatinine, Urea, Alanine aminotransferase, Aspartate aminotransferase, Gamma glutamyl transferase, Total bilirubin, Total protein, Albumin, Alkaline phosphatase, Serum uric acid, Glucose, Triglycerides, Total cholesterol, High-density lipoprotein cholesterol, Low-density lipoprotein cholesterol

    Time frame: Up to Day 14

  4. Incidence of Adverse events in terms of changes in Physical examinations

    Review of body weight and height; general appearance; head; eyes; ears/nose/throat; neck; lymph nodes; neurological and musculoskeletal systems; heart; lungs; abdomen; skin; and extremities

    Time frame: Up to Day 14

  5. Incidence of Adverse events in terms of changes in Vital signs

    Oral temperature, respiratory rate, blood pressure, and pulse rate

    Time frame: Up to Day 14

  6. Incidence of Adverse events in terms of changes in 12-lead ECGs

    The 12-lead ECGs must be recorded after the subjects have rested in the supine position for 5 minutes to ensure a stable baseline.

    Time frame: Up to Day 14

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) (of single dose and at stable status)

    Time frame: Up to Day 10

  2. Area under the plasma concentration versus time curve (AUC) (of single dose and at stable status)

    Time frame: Up to Day 10

  3. Half-time (T1/2) (of single dose and at stable status)

    Time frame: Up to Day 10

  4. Time to the peak plasma concentration (Tmax) (of single dose and at stable status)

    Time frame: Up to Day 10

  5. Changes in serum uric acid concentration from baseline

    Time frame: Up to Day 10

  6. Changes in urinary uric acid excretion from baseline

    Time frame: Up to Day 10

07

Study locations

1 site
  • Atridia Pty Limited
    Sydney, New South Wales 2000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Feb 2018, 7 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 7 months is above that.

Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2017
First posted
Jul 7, 2017
StartActual
Jul 4, 2017
Primary completionActual
Feb 15, 2018
CompletionActual
Feb 15, 2018
Last update
Mar 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03211403
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Jul 7, 2017
Start date
Jul 4, 2017
Primary completion
Feb 15, 2018
Completion
Feb 15, 2018
Last update
Mar 21, 2018

Study contacts

Sam Salman, B.Sc.BMBS
principal investigator · Linear Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion